A new peptide developed by researchers in Temple University's College of Science and Technology has demonstrated efficacy against triple negative breast cancer. The leptin receptor antagonist peptide, developed by researchers Laszlo Otvos and Eva Surmacz, could become an attractive option for triple negative breast cancer treatment, especially in the obese patient population...
More...